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ABSTRACT 
 
Introduction: We estimated the cost effectiveness of different cognitive screening tests for use 
by General Practitioners (GPs) to detect cognitive impairment in England. 
 
Methods: A patient-level cost-effectiveness model was developed using a simulated cohort 
that represents the elderly population in England (65 years and older). Each patient was 
followed over a life time period. Data from published sources were used to populate the model. 
The costs include government funded health and social care, private social care, and informal 
care. Patient health benefit was measured and valued in Quality Adjusted Life Years (QALYs). 
 
Results: Base-case analyses found that adopting any of the three cognitive tests (MMSE, 6CIT, 
or GPCOG) delivered more QALYs for patients over their life-time and made savings across 
sectors including health care, social care, and informal care compared with GP unassisted 
judgement. The benefits were due to early access to medications. Among the three cognitive 
tests, adopting the GPCOG was considered the most cost-effective option with the highest 
Incremental Net Benefit (INB) at the threshold of £30,000 per QALY from both the NHS PSS 
perspective (£195,034 per 1000 patients) and the broader perspective that includes private 
social care and informal care (£196,251 per 1000 patients). Uncertainty was assessed in both 
deterministic and probabilistic sensitivity analyses.  
 
Conclusions: Our analyses indicate that the use of any of the three cognitive tests by GPs could 
be considered a cost-effective strategy compared with GP unassisted judgement. The most cost-
effective option in the base-case was the GPCOG.   
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1. INTRODUCTION 
 
Timely diagnosis has consistently been a top priority in recent policies for dementia care in the 
United Kingdom (UK) (Department of Health, 2015) and around the world (Prince et al., 2011, 
World Health Organisation, 2012). The National Dementia Strategy (NDS) was launched in 
England in 2009, highlighting the issue of under-diagnosis in dementia and setting the objective 
to improve dementia diagnosis rates (Health & Social Care Information Centre, 2014). 
 
As a result of the NDS, more and more people have been diagnosed with dementia (Mukadam 
et al., 2014). This implies an increase in the number of cognitive-impairment cases assessed 
and referred by GPs. Timely diagnosis for people with dementia in England is related to the 
performance of primary care teams detecting people with dementia with a degree of accuracy 
and referring them to memory services. However, evidence suggests that it is difficult for GPs 
to identify those with Mild Cognitive Impairment (MCI) and mild dementia (Mitchell et al., 
2011). In their meta-analysis, Mitchell et al. (2011) found that the accuracy of GP clinical 
judgement (unassisted) is low for detecting dementia, especially those in the early stages of 
dementia or those with pre-dementia MCI. 
 
This study aims to investigate the cost-effectiveness of using the three most commonly used 
cognitive screening tests for detecting cognitive impairment in primary care in England: 
MMSE, GPCOG, and 6CIT. Our recent survey1 found 29% of GPs in the UK used 6CIT; 26% 
used MMSE; and 21% used GPCOG to screen for patients with dementia. The baseline 
comparator is GP unassisted judgement.  
 
2. METHODS 
 
A patient-level cost-effectiveness model was developed to include the dementia pathway from 
pre-diagnosis to post-diagnosis, disease progression and death. The clinical disease and service 
pathway were developed by interviews with clinicians, commissioners, and other experts in 
dementia care. 
                                                          
1 The survey was conducted in the GP section of an online forum for doctors in the UK (www.doctors.net.uk)  
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This model only examines dementia in the $O]KHLPHU¶V GLVHDVH $' form. The simulated 
population represented the English population 65 years and older. Each patient was tracked 
over a life time period. Benefits were measured in terms of QALYs gained for patients. The 
QALY is a measure of health benefit that captures both impacts on morbidity (health-related 
quality of life [HRQOL]) and where relevant mortality (length of life in life years). It does this 
by assigning each year of life a value on a scale where full health is one and states as bad as 
being dead zero (Brazier et al., 2007). The benefit of GP-based diagnostic interventions comes 
from improving HRQOL RYHUWKHSDWLHQWV¶ life. Costs include government health and social 
care, private payment for social care, and unpaid informal care. A detailed input data table is 
provided in appendix 1. All costs were reported in pounds sterling in year 2016 prices, and all 
outcomes were discounted at 3.5% per year. The simulation software SIMUL8® (SIMUL8, 
2014) was used to implement the model. 
 
2.1. Model structure  
 
The conceptual models are illustrated in figure 1a and 1b. The model starts by simulating a 
cohort of patients and assigning each patient a set of unique characteristics (e.g. age, gender, 
disease status, etc.). The cohort includes a representative sample of the general population. The 
same cohort is analysed for four scenarios: (1) GP¶s unassisted judgement; and GPs administer 
either MMSE (2); 6CIT (3); or GPCOG (4). 
 
---Insert figure 1 and 2 about here ---- 
 
Patients are followed up, with their characteristics updated every year until they die. Patients 
move between four health states as described in figure 1: normal cognition (not having 
dementia or MCI), MCI, dementia, and death. For patients in the dementia state, their dementia 
progresses every year in terms of worsening cognition (measured by MMSE score), behaviours 
(measured by Neuro Psychiatric Inventory [NPI] score), and functioning in activities of daily 
living (measured by Activities of Daily Living [ADL] and Instrumental Activities of Daily 
Living [IADL] scores). Due to dementia symptoms, patients in the dementia state also have a 
raised risk of being institutionalised. 
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Figure 2 describes the healthcare events (service pathway) in the model. The model annually 
checks the status of a patient to see whether they have already had a dementia diagnosis; 
whether they have already been diagnosed with MCI and is currently being followed up by 
memory services; and whether they would receive an assessment for cognitive impairment by 
GPs this year. Depending on the outcome, the model sends the patient to the relevant route (see 
figure 2). Since the focus of the evaluation is on interventions for GP-based assessment of 
cognitive impairment, memory services were assumed to be able to diagnose all cases with 
100% accuracy. Newly diagnosed dementia patients receive dementia medications. Newly 
diagnosed MCI patients are followed up by memory services for two years. Confirmed non-
cases (not dementia or MCI) just return to the population. 
 
The model updates patient characteristics at the end of the year. All patients face an annual 
mortality rate based on their age, gender and dementia status. If a patient survives the year, the 
model will send him/her to another cycle of events for the next year. If a patient dies, he/she 
will exit the model and have their total costs and QALYs calculated. 
 
2.2. Input Data 
 
2.2.1. The cohort 
 
The distributions of age and gender for the cohort were based on the mid-2013 data from the 
Office for National Statistics (ONS, 2015). The prevalence of dementia and dementia severity, 
according to age and gender, was based on the recent dementia UK report (Prince et al., 2014). 
The prevalence of MCI was based on a UK study (Fish et al., 2008). 
 
2.2.2. Parameters relating to the GP assessment for cognitive impairment: 
 
a. Annual probability of having a GP assessment for cognitive impairment: 
 
If a patient has not had a diagnosis of dementia or is not being followed up by memory services, 
they can be assessed by GPs for dementia within any given year. Since a national dementia 
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screening programme is not implemented in England, the annual probability for a 65+ patient 
to receive a dementia assessment by GPs should be less than 100%. 
 
We estimated the number of new dementia diagnoses per year and the proportion of 
undiagnosed dementia cases diagnosed per year using published data (Health & Social Care 
Information Centre, 2014). Using the average sensitivity of GPs for assessing dementia, we 
estimated the proportion of undiagnosed individuals with dementia, who had a GP assessment 
for dementia per year at 21.63% (range: 13.00% - 27.26%). 
 
Abdel-Aziz and Larner (2015) reported the diagnostic outcomes of patients who were referred 
to a memory clinic in England in one year. Using their reported proportions, we estimated the 
relative numbers of referred cases for MCI and referred non-cases (not dementia or MCI) from 
the number of new diagnoses of dementia per year. Knowing the prevalence of dementia and 
MCI in the simulated cohort, we estimated the relative proportions of MCI and non-cases who 
were diagnosed by memory services per year. Then, using the average sensitivity of GPs for 
MCI and the average specificity of GPs for non-case, we estimated the proportions of MCI and 
non-cases who would have a GP assessment for cognitive impairment per year: 10.53% (range: 
6.33% - 13.27%) for MCI; and 18.17% (range: 10.92% - 22.89%) for non-cases (not impaired). 
 
b. Sensitivity and specificity of the 6CIT compared with the MMSE: 
 
It was assumed that severe dementia was always detected with 100% sensitivity by GPs 
regardless of the screening tool. This assumption is similar to one used in a published 
diagnostic model for AD (Biasutti et al., 2012). Thus, the effect of GP-based interventions only 
comes into play in detecting mild dementia, moderate dementia, MCI and non-cases. 
 
Table 1 shows the sensitivity and specificity of each assessment strategy.  
 
---Insert Table 1 about here --- 
 
Data from three studies were used to derive the relative sensitivity and specificity for each 
strategy. The first one is a UK pragmatic diagnostic accuracy study of the use of 6CIT in 
primary care settings (Abdel-Aziz and Larner, 2015). The performance of 6CIT in detecting 
dementia and MCI was compared to that of the simultaneously administered MMSE. The 
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relative sensitivity and specificity of the GPCOG was derived from an Australian study 
(Brodaty et al., 2002) and the relative sensitivity and specificity for the unassisted strategy (no 
cognitive test) was derived from a UK study (O'Connor et al., 1988). 
 
c. Cost per assessment for different strategies: 
 
The base cost per assessment for each strategy includes one GP consultation, one practice nurse 
consultation and laboratory tests (NICE, 2010). 
 
The MMSE is associated with a small license fee of £0.96 per test (PAR, 2016), whereas the 
6CIT and GPCOG are free. Furthermore, their administration time per assessment is different 
(Cordell et al., 2013): the MMSE requires 7-10 minutes; GPCOG requires 2-5 minutes; and 
6CIT requires 4-6 minutes. This difference in administered time is converted to healthcare costs 
by multiplying with the cost per minute of a GP in a surgery. Sensitivity analyses explored the 
results when using the cost per minute of a nurse for administration time. 
 
2.2.3. Parameters for the transitions between health states 
 
Transition from normal cognition to MCI was described in the model as an annual probability 
of having MCI for normal cognition patients. Ward et al. performed a systematic review of 
estimates for MCI prevalence and incidence. They found 13 studies reporting incidence of 
MCI; among them, five studies reporting age-stratified rates (none of the studies were UK 
studies) (Ward et al., 2012). The annual probability in our base-case analysis was derived from 
the pooled data of five studies which reported MCI incidence rates in Italy, Germany, Sweden, 
and France. 
 
The annual probability of having dementia for not-impaired patients was derived from data for 
dementia incidence rates in England and Wales (Matthews and Brayne, 2005). All new incident 
dementia was modelled as undiagnosed mild dementia in community.  
 
MCI patients were modelled to have two types of transitions: some of them progressed to 
dementia; some of them reverted to normal cognition. The data for the annual conversion rate 
from MCI to dementia was from a meta-analysis of 41 robust inception cohort studies (Mitchell 
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and Shiri-Feshki, 2009). For people with MCI who revert to normal cognition, the annual rate 
was derived from a UK study on 3,020 individuals diagnosed with MCI (Koepsell and Monsell, 
2012). 
 
2.2.4. Parameters for dementia progression  
 
Progression was described in terms of annual worsening rates for MMSE, NPI, ADL and IADL 
measures. The annual declining rate for MMSE score was derived from the Consortium to 
Establish A Registry IRU$O]KHLPHU¶V'LVHDVH&(5$' data, whereas the equations for the 
worsening in terms of NPI, ADL, and IADL were estimated from data collected in donepezil 
trials (Getsios et al., 2010). 
 
People with dementia living in community also have an annual probability of 
institutionalisation based on their MMSE score. The probability was calculated based on a 
published equation (Nagy et al., 2011) that used data from a UK-based study (Stewart, 1997). 
 
2.2.5. Effectiveness of dementia medications: 
 
NICE currently recommends donepezil, rivastigmine, or galatamine for mild to moderate AD; 
whereas memantine is recommended for severe AD, or moderate AD who are intolerant of 
other dementia medications (NICE, 2015). It was assumed that all diagnosed mild to moderate 
dementia were given donepezil 10 mg once daily whereas diagnosed severe dementia were 
given memantine 10 mg once daily. 
 
The improvement in clinical scores for donepezil and memantine was based on the meta-
analysis results reported in the recent Health Technology Assessment (HTA) report (Bond et 
al., 2012). Being consistent with previous models, the clinical improvement was assumed to 
only occur in the first year (symptomatic effect), after that, patients would not gain any further 
improvement while remaining on the medication; they would progress at the same rate as 
untreated patients.  
 
2.2.6. Mortality 
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The age and gender-specific annual mortality rates from the national life tables were applied 
for people with normal cognition and people with MCI in the simulation. For people with 
dementia, a relative risk of death was used to adjust their annual mortality rates (Helmer et al., 
2001). 
 
2.2.7. Costs 
 
Data for health, social care, and informal care costs were from the largest and most recent cost 
study for dementia in the UK: the dementia UK report (Prince et al., 2014). This study 
estimated the annual figures for the UK for 2013 using the best currently available information. 
According to this report, healthcare costs were met entirely by the National Health Service 
(NHS) whereas social care costs were met partly by local authorities and partly by people with 
dementia themselves through self-funding.  
 
The cost of medications (donepezil and memantine) for diagnosed dementia are from British 
National Formulary (BNF) accessed in 2016 (BNF, 2016). Patients receiving medications were 
assumed to incur costs associated with biannual visits to a physician (Getsios et al., 2010). 
 
2.2.8. Health utilities 
 
The recent UK HTA did not find any study which provides utility values for people with AD 
in the UK (Bond et al., 2012). They chose the study by Jonsson et al. (2006) which reports EQ-
5D valuations of utility across different MMSE scores from people with AD in Sweden, 
Denmark, Finland, and Norway (Jonsson et al., 2006). Getsios et al. (2010) in their cost 
effectiveness analysis of donepezil in the UK also used the published regression equation for 
AD patient EQ-5D scores from Jonsson et al. (2006) with a slight modification for the NPI 
term: the coefficient for the NPI term was modified to correspond to the full NPI scale because 
Jonsson et al. (2006) used the brief version of the NPI. The same equation reported in (Getsios 
et al., 2010) was used in our model. 
 
The evidence for the utility of the informal caregivers of people with dementia is limited (Bond 
et al., 2012). Being consistent with the recent HTA model (Bond et al., 2012), caregiver utility 
was not included in our base-case analyses. 
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2.3. Analyses 
 
The PRGHO¶VFRQFHSWXDOVWUXFWXUHZDVYDOLGDWHGE\FKHFNLQJZLWKWKUHHH[SHUWV LQGHPHQWLD 
care: a neurologist, a dementia lead, and a GP. The model codes were verified internally 
throughout the model implementation. Simulated patients were checked to make sure they 
behaved logically as expected i.e. their characteristics were changing and they followed 
expected routes. 7KHRXWSXWV IRUFRVWVDQGKHDOWKXWLOLW\ZHUHFKHFNHGDJDLQVW WKHSDWLHQW¶V
other characteristics. The model estimates were also checked to see if they agreed with the 
input data. 
 
Uncertainty in key inputs into the model was examined through sensitivity analysis. A 
deterministic sensitivity analysis (DSA) was undertaken where we examined the impact of 
specific ranges in possible values for each input variable one at a time. A more sophisticated 
probability sensitivity analysis (PSA) was undertaken where all key variables are varied at the 
same time and the values are sampled from a distribution of values given to each variable.  
 
3. RESULTS 
 
3.1. Base-case Analyses 
 
Table 2 reports the base-case results. Adopting any of the cognitive tests delivered more 
QALYs and saved costs compared to the baseline scenario (GP unassisted judgement). The 
benefits were due to early access to AD medications.  
 
--- Insert Table 2 about here --- 
 
Among the three cognitive tests, the 6CIT resulted in the most QALYs gained (3.48 QALYs 
per 1000 patients). This is because the 6CIT has the highest sensitivity (patients were diagnosed 
earlier).   
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Regarding costs, overall, the GPCOG made the highest saving (£187,064 per 1000 patients) 
compared to the MMSE (£66,566 per 1000 patients) and the 6CIT (£7,485 per 1000 patients). 
This mainly came from saving in health care resources. The GPCOG has the highest specificity 
therefore less false positive cases were sent to memory services when it was used. Although 
the 6CIT made the highest savings for government social care, private social care, and informal 
care (thanks to earlier diagnosis and access to dementia medications), the total amount was still 
less than the saving in healthcare resources by the GPCOG.   
 
The Incremental Net Benefit (INB) is the overall incremental value in a monetary unit. It is 
calculated by subtracting the incremental cost from the multiplication of the incremental 
QALYs and the cost-effectiveness (CE) threshold. A positive INB means the intervention is 
cost-effective compared to the baseline option. At the CE threshold of £30,000 per QALY, the 
INBs of the three interventions (MMSE, 6CIT, and GPCOG) are positive from both the NHS 
PSS perspective and the broader perspective. The GPCOG option has the highest INB among 
the three interventions. Thus, at the NICE referenced threshold (£30,000 per QALY), all three 
interventions were considered cost-effective and the GPCOG was considered the best option.  
 
3.2. One-way Sensitivity Analyses  
 
One-way sensitivity analyses (Table 3) show that the results for INBs are robust in most 
scenarios. The interventions made savings and delivered more QALYs in all sensitivity 
scenarios compared to unassisted GPs. The results are most sensitive to assumptions about the 
effectiveness of dementia medications. When the assumed duration for the symptomatic 
improvement with medication was increased to three years, the GPCOG was no longer the 
option with the highest INB; the 6CIT became the best option with the highest INB. However, 
this is quite unlikely given the current evidence for clinical effectiveness of AD medications 
(Bond et al., 2012).  
 
--- Insert Table 3 about here --- 
 
3.3. Probability sensitivity analyses (PSA)  
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Figure 3 shows the cost-effectiveness acceptability curve (CEAC) in our PSA. At the CE 
threshold of £30,000 per QALY, the probability of the GPCOG being the best option was 75% 
from the NHS PSS perspective and 71.8% from the broader perspective. The probability of the 
&,7EHLQJWKHEHVWRSWLRQEHFDPHKLJKHUWKDQWKH*3&2*¶V when the threshold was above 
£50,000 per QALY from the NHS PSS perspective and £47,000 per QALY from the broader 
perspective. 
 
--- Insert Figure 3 about here ---  
 
4. DISCUSSION AND CONCLUSIONS 
 
The study reported in this paper is the first to evaluate the cost-effectiveness of GPs using 
different cognitive screening tests compared with their unassisted judgement in England. The 
patient-level simulation model developed for the evaluation captured the pathway from normal 
ageing to the development of cognitive impairment and the dementia progression.  
 
Our analyses estimated that using any of the three cognitive screening tests was more cost-
effective than the GP unassisted judgement. Among the three cognitive tests, the GPCOG was 
considered the most cost-effective option for the NHS given the referenced NICE threshold. 
The results are sensitive to assumptions about the effectiveness of dementia medications. The 
model results should be treated with caution because of the following limitations in our 
analyses. 
 
First, the model assumed all dementia followed the pattern of the AD sub-type. However, there 
are also other dementia sub-types which can have some different features besides the common 
characteristics of dementia. For example, people with vascular dementia can have higher risk 
of recurrent strokes which can significantly reduce their quality of life and chance of survival 
(Bermingham, 2014). 
 
Second, memory services were assumed to always be able to correctly diagnose dementia, 
MCI, and non-cases. However, in reality, there might be false negatives and false positives 
made by memory services. False positive diagnoses could have negative impact on patient 
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quality of life but evidence is limited. Our model can be improved in the future by relaxing that 
assumption when more data are available. 
 
Third, the model assumed that diagnosed dementia was only given AD medications. However, 
there could be a wide range of other treatment options and support for diagnosed dementia in 
practice. The evidence for the effectiveness of those interventions is limited, although some of 
them could improve the quality of life for patients and caregivers (Knapp et al., 2013). 
 
Finally, data are not available to accurately estimate all model parameters. The study had to 
combine the best available evidence from different sources to estimate the model inputs. 
Nevertheless, we have addressed this uncertainty in our deterministic and probabilistic 
sensitivity analysis.  
 
The results in this study are specific for the situation in England. The model structure and logic 
can be generalised to similar healthcare systems, though the input estimates would need to be 
adjusted to reflect the situation in other countries. The model code (SIMUL8 and Visual Basic 
Application) can be made available on request to others who are interested in adapting the 
model to other contexts. 
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Figure 1: the conceptual model: patient health states and disease progression 
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Figure 2: the conceptual model: healthcare events  
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Figure 3: Cost-effectiveness acceptability curves  
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Table 1: Sensitivity and specificity of assessment strategies   
 
 Mean and Range (95% CI)  Data source 
Sensitivity 
(dementia) 
Sensitivity 
(MCI) 
Specificity 
(no dementia) 
Specificity 
(no MCI) 
GP 
unassisted 
judgement 
0.58  
(0.38 ± 0.78) 
0.50  
(0.35 ± 0.65) 
0.75  
(0.66 ± 0.80) 
0.66  
(0.58 ± 0.74) 
Computed based 
on (O'Connor et 
al., 1988) 
MMSE 0.59  
(0.39 ± 0.80) 
0.51  
(0.36 ± 0.66) 
0.85 
(0.79 ± 0.91) 
0.75  
(0.66 ± 0.84) 
(Abdel-Aziz and 
Larner, 2015) 
 
6CIT 0.88  
(0.78 ± 0.97) 
0.66  
(0.54 ± 0.77) 
0.78  
(0.72 ± 0.84) 
0.70  
(0.62 ± 0.78) 
GPCOG 0.60  
(0.39 ± 0.81) 
0.52  
(0.36 ± 0.67) 
0.93  
(0.82 ± 0.99) 
0.82  
(0.72 ± 0.92) 
computed based 
on (Brodaty et al., 
2002) 
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Table 2: Base-case results (per 1000 patients)  
 Incremental results (compared to baseline) 
Per 1000 patients  MMSE 6CIT GPCOG 
COSTS 
Diagnostic costs, GPs  £42,394   £23,212   £16,838  
Diagnostic costs, memory services -£107,993  -£40,793  -£203,655  
Medications  £1,686   £39,174   £3,938  
Other health care -£1,708  -£18,423  -£2,657  
Government social care, community  £0  -£671  -£70  
Government social care, institutional -£134  -£1,806  -£241  
Total government health and social care -£65,755   £693  -£185,846  
Private social care costs, community  £0    -£447  -£47  
Private social care costs, institutional -£249  -£3,354  -£447  
Informal care costs -£562 -£4,377 -£723 
Total all costs -£66,566  -£7,485  -£187,064  
QALYS 
QALYs (patient) 0.1031 3.4847 0.3063 
Incremental Net Benefit at the threshold of £30,000 per QALY 
From the NHS PSS perspective   £68,848   £103,848   £195,034  
From the broader perspective   £69,659   £112,027   £196,251  
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Table 3: One-way sensitivity analysis results (per 1000 patients) 
Sensitivity Analysis Scenario  
Incremental Net Benefit per 1000 patients at the threshold of £ 30,000 per QALY 
From NHS PSS Perspective From the broader perspective  
MMSE 6CIT GPCOG MMSE 6CIT GPCOG 
Base case £68,848 £103,848 £195,034 £69,659 £112,027 £196,251 
Medication symptomatic improvement duration 
increased to 3 years £72,738 £262,799 £207,230 £73,942 £285,240 £209,197 
Medication effectiveness  Upper 95% CI value £70,876 £190,404 £201,966 £71,687 £203,739 £203,404 
Lower 95% CI value  £66,869 £22,921 £188,409 £67,680 £28,770 £189,466 
Annual medication costs 
(including monitoring costs) 
Ÿ £68,426 £94,055 £194,050 £69,237 £102,233 £195,267 
ź-25% £69,269 £113,642 £196,019 £70,080 £121,820 £197,236 
Annual probability of being 
assessed by GP 
Upper range value  £86,720 £123,128 £247,034 £87,407 £134,005 £248,752 
Lower range value  £39,140 £106,767 £116,630 £39,541 £114,632 £117,420 
No license fee for using MMSE £70,148 £103,848 £195,034 £70,959 £112,027 £196,251 
Nurses administered the test  £98,537 £121,165 £207,251 £99,348 £129,344 £208,468 
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Appendix 1:  Input data 
 
Item
Costs Severity Quantity Value Value Unit Price Year Source
12 minutes 36 £ 2009
12 minutes 10 £ 2009
per assessment 55.0 £ 2009
per assessment 650.0 £ 2012 Prince, 2014
per assessment 0.96 £ 2016 PAR,2016
Donepezil 10 mg tablet once a day mild-mod per person/year 446.9 £ 2016
Memantine 10 mg tablet once a day severe per person/year 312.7 £ 2016
per person/ year 100.0 £ 2007 Getsios, 2010 
Mild per person/ year 2751.0 £ 2012
Moderate per person/ year 2695.0 £ 2012
Severe per person/ year 11258.0 £ 2012
Mild per person/ year 4504.0 £ 2012
Moderate per person/ year 9438.0 £ 2012
Severe per person/ year 8689.0 £ 2012
Mild per person/ year 3121.0 £ 2012
Moderate per person/ year 7772.0 £ 2012
Severe per person/ year 10321.0 £ 2012
Mild per person/ year 24737.0 £ 2012
Moderate per person/ year 25715.0 £ 2012
Severe per person/ year 25874.0 £ 2012
Mild per person/ year 19714.0 £ 2012
Moderate per person/ year 32237.0 £ 2012
Severe per person/ year 33482.0 £ 2012
Mild per person/ year 1067.0 £ 2012
Moderate per person/ year 2901.0 £ 2012
Severe per person/ year 2119.0 £ 2012
Informal care, residential care
% community social care funded privately 0.4
% residential social care funded privately 0.65
MMSE license fee
BNF, 2016
Post-diagnosis monitoring
Other healthcare, community
Prince, 2014
Other healthcare, institutionalisation
Social care, community
Social care, institutionalisation
Informal care, community
Data
Costs of a GP consultation
NICE, 2010Cost of a practice nurse consultation
Base cost for a GP cognitive assessment
Cost of a specialist assessment (memory service)
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Effect
-2.683 -5.673 0.207
-1.6 -4.762 1.54
1.24 0.81 1.66
0.7 0.02 1.38
2.02 1.06 3.28
1.41 0.04 2.78
MCI incidence per 1000 person-years
Dementia incidence per 1000 person-years
Female
6.3
6.1
14.8
31.2
71.7
Progressing from MCI to dementia Mitchell and Shiri-Feshki, 2009
Reverting from MCI to normal cognition Koepsell and Monsell, 2012
Mean
1.82 1.77 2.68
Memantine vs placebo
12.30
17.75
32.73
On MMSE 
Donepezil vs placebo
Memantine vs placebo
On ADCS-ADL
Donepezil vs placebo
Medication effectiveness
Donepezil vs placebo
Memantine vs placebo
95% CI
On NPI 
Bond et al., 2012
31.67
23.33
Age group
MCI incidence
65 to 69 
70 to 74
75 to 79 
80 to 84
85+
Dementia incidence 
65 to 69 
70 to 74
75 to 79 
80 to 84
85+
Age group
6.9
Ward et al., 2012
Helmer et al., 2001
Annual rate
Annual rate
Relative risk of death for dementia
95% CI
58.4
Matthews and Brayne, 2005
0.049
14.5
14.2
17
0.16
Male
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Patient Utility
Getsios et al., 2010 
MMSE progression
NPI progression
ADL progression
IADL progression
Annual probability of institutionalisation Nagy et al., 2011
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Appendix 2: Simul8 Schematic for the model  
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Appendix 3: Results from our online survey on www.doctors.net.uk 
Question for GPs: What screening test do you most often use for dementia?  
Cognitive screening test  Responses  Percentage 
6-Item Cognitive Impairment Test (6CIT) 30 29 (%)  
Mini-Mental State Examination (MMSE) 27 26 (%) 
General Practitioner Assessment of Cognition (GPCOG) 21 21 (%) 
Abbreviated Mental Test Score (AMTS) 7 7 (%) 
Montreal Cognitive Assessment (MoCA) 6 6 (%) 
Mini-cog  2 2 (%) 
Addenbrookes Cognitive Examination-III (ACE-III) 1 1 (%) 
Others 8 8 (%) 
Total  102 100 (%) 
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